Fake news. Wrong place to look at. Here is the evidence.
Remestemcel-L is application to Center for Biologics Evaluation and Research (CBER).
https://www.fda.gov/media/141131/download
The page "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page" is for Center for Drug Evaluation and Research (CDER).
If you click on search this month you will find this line:
"Drug Approval Reports by MonthSelect a Report:Reports include only BLAs/NDAs/ANDAs or supplements to those applications approved by the Center for Drug Evaluation and Research (CDER) and tentative NDA/ANDA approvals in CDER. The reports do not include applications or supplements approved by the Center for Biologics Evaluation and Research (CBER)."
https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2020-biological-device-application-approvals is the latest CBER approvals.
MSB officially rejected?, page-24
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |